FDA Sentinel Initiative Needs Safeguards To Protect Industry And Patients
This article was originally published in The Gray Sheet
Executive Summary
A greatly expanded drug and device surveillance program could do more harm than good without proper safeguards in place, according to participants at a Dec. 16 FDA-sponsored workshop